New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population

Annals of Pharmacotherapy

Volumn 50, Issue 2, 2016, Pages 133-140

  Campbell, Christopher T ^a,b   McCaleb, Rachael ^c   Manasco, Kalen B ^b  

^a Georgia Regents Medical Center   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

amikacin; cystic fibrosis; inhaled antibiotic; levofloxacin; vancomycin

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; LEVOFLOXACIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; RETROSPECTIVE STUDY; REVIEW; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84954350106     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015621916     Document Type: Review

References (21)

1. M.N.HurleyT.M.McKeeverA.P.PrayleA.W.FogartyA.R.Smyth. Rate of improvement of CF life expectancy exceeds that of general population: observational death registration study. J Cyst Fibros. 2014;13:410-415. doi:10.1093/jac/dkn059.
2. P.J.MogayzelE.T.NaureckasK.A.Robinson. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med. 2013;187:680-689. doi:10.1164/rccm.201207-1160OE.
3. S.Conway. Evidence for using nebulized antibiotics in cystic fibrosis. Arch Dis Child. 1999;80:307-309. doi:10.1136/adc.80.4.307.
4. D.ConoleG.M.Keating. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs. 2014;74:377-387. doi:10.1007/s40265-014-0181-0.
5. Cystic Fibrosis Foundation. Drug development pipeline. https://tools.cff.org/research/drugdevelopmentpipeline/. Accessed September 19, 2015.
6. C.M.OliphantG.M.Green. Quinolones: a comprehensive review. Am Fam Physician. 2002;65:455-464.
7. D.S.ArmstrongK.GrimwoodJ.B.Carlin. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21:267-275.
8. M.N.DudleyJ.LoutitD.C.Griffith. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol. 2008;19:637-643.
9. D.E.GellerP.A.FlumeD.Griffith. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011;55:2636-2640.
10. D.E.GellerP.A.FlumeD.Staab. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis withPseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183:1510-1516. doi:10.1164/rccm.201008-1293OC.
11. J.S.ElbornD.E.GellerD.Conrad. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015;14:507-514. doi:10.1016/j.jcf.2014.12.013.
12. P.MeersM.NevilleV.Malinin. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61:859-868. doi:10.1093/jac/dkn059.
13. J.P.ClancyM.W.KonstanJ.Billings. Phase II studies of nebulized Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68:818-825. doi:10.1136/thoraxjnl-2012-202230.
14. S.L.Hewer. Inhaled antibiotics in cystic fibrosis: what’s new?J R Soc Med. 2012;105:S19-S24. doi:10.1258/jrsm.2012.12s004.
15. O.O.OkusanyaS.M.BhavnaniJ.P.Hammel. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrob Agents Chemother. 2014;58:5005-5015. doi:10.1128/AAC.02421-13.
16. D.K.LoM.N.HurleyM.S.Muhlebach. Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev. 2015;(2):CD009650. doi:10.1002/14651858.CD009650.pub3.
17. M.MacfarlaneA.LeaveyJ.McCaughan. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect. 2007;65:231-236.
18. A.SolisD.BrownJ.Hughes. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol. 2003;36:189-195.
19. S.J.DoeA.McSorleyB.Isalska. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros. 2010;9:104-109. doi:10.1016/j.jcf.2009.11.009.
20. L.MáizR.CantónN.MirF.BaqueroH.Escobar. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol. 1998;26:287-289.
21. D.HayesJrB.S.MurphyT.W.MullettD.J.Feola. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology. 2010;15:184-186.